Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling.

Tong A, Kelly S, Nusbaum R, Graves K, Peshkin BN, Valdimarsdottir HB, Wood M, McKinnon W, Garber J, McCormick SR, Jandorf L, Schwartz MD.

Psychooncology. 2015 Jan;24(1):33-9. doi: 10.1002/pon.3560. Epub 2014 May 17.

2.

Current strategies for the prevention of breast cancer.

Advani P, Moreno-Aspitia A.

Breast Cancer (Dove Med Press). 2014 May 2;6:59-71. doi: 10.2147/BCTT.S39114. eCollection 2014. Review.

3.

Lower mitotic activity in BRCA1/2-associated primary breast cancers occurring after risk-reducing salpingo-oophorectomy.

van Verschuer VM, Heemskerk-Gerritsen BA, van Deurzen CH, Obdeijn IM, Tilanus-Linthorst MM, Verhoef C, Schmidt MK, Koppert LB, Hooning MJ, Seynaeve C.

Cancer Biol Ther. 2014 Apr;15(4):371-9. doi: 10.4161/cbt.27628. Epub 2014 Jan 14.

4.

Baseline E(2) levels are higher in BRCA2 mutation carriers: a potential target for prevention?

Kim J, Oktay K.

Cancer Causes Control. 2013 Mar;24(3):421-6. doi: 10.1007/s10552-012-0127-3. Epub 2012 Dec 28.

5.

Comparison of Random Periareolar Fine Needle Aspirate versus Ductal Lavage for Risk Assessment and Prevention of Breast Cancer.

Hoffman A, Pellenberg R, Drendall CI, Seewaldt V.

Curr Breast Cancer Rep. 2012 Sep;4(3):180-187. Epub 2012 Jun 22.

6.

Cognitive and psychological impact of BRCA genetic counseling in before and after definitive surgery breast cancer patients.

Christie J, Quinn GP, Malo T, Lee JH, Zhao X, McIntyre J, Brzosowicz J, Jacobsen PB, Vadaparampil ST.

Ann Surg Oncol. 2012 Dec;19(13):4003-11. doi: 10.1245/s10434-012-2460-x. Epub 2012 Jul 6.

7.

Ovarian cancer: diagnosis and treatment.

Wenderlein JM.

Dtsch Arztebl Int. 2012 Mar;109(11):208; author reply 208-9. doi: 10.3238/arztebl.2012.0208a. Epub 2012 Mar 16. No abstract available.

8.

Involvement of ER-α36, Src, EGFR and STAT5 in the biphasic estrogen signaling of ER-negative breast cancer cells.

Zhang XT, Ding L, Kang LG, Wang ZY.

Oncol Rep. 2012 Jun;27(6):2057-65. doi: 10.3892/or.2012.1722. Epub 2012 Mar 15.

9.

Genetics for the general internist.

Laukaitis CM.

Am J Med. 2012 Jan;125(1):7-13. doi: 10.1016/j.amjmed.2011.07.034. Epub 2011 Nov 11. Review.

10.

SI RLTD: Risk Scores and Decision Making: The Anatomy of a Decision to Reduce Breast Cancer Risk.

Holmberg C, Daly M, McCaskill-Stevens W.

J Nurs Healthc Chronic Illn. 2010 Dec;2(4):271-280.

11.

Fighting breast cancer: a call for a new paradigm.

Binstock M.

Perm J. 2005 Winter;9(1):73-6. No abstract available.

PMID:
21687489
Free PMC Article
12.

Breast cancer prevention in women with a BRCA1 or BRCA2 mutation.

Metcalfe KA, Narod SA.

Open Med. 2007;1(3):e184-90. Epub 2007 Dec 18. No abstract available.

PMID:
21673951
Free PMC Article
13.

Development and evaluation of a decision aid for BRCA carriers with breast cancer.

Culver JO, MacDonald DJ, Thornton AA, Sand SR, Grant M, Bowen DJ, Burke H, Garcia N, Metcalfe KA, Weitzel JN.

J Genet Couns. 2011 Jun;20(3):294-307. doi: 10.1007/s10897-011-9350-4. Epub 2011 Mar 3. Erratum in: J Genet Couns. 2013 Jun;22(3):406.

14.

Risk-reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery.

Salhab M, Bismohun S, Mokbel K.

BMC Womens Health. 2010 Oct 20;10:28. doi: 10.1186/1472-6874-10-28. Review.

15.

A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells.

Zhang XT, Kang LG, Ding L, Vranic S, Gatalica Z, Wang ZY.

Oncogene. 2011 Feb 17;30(7):770-80. doi: 10.1038/onc.2010.458. Epub 2010 Oct 11.

16.

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Pichert G, Van t'veer L, Tung N, Weitzel JN, Couch FJ, Rubinstein WS, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Schildkraut J, Blum JL, Rebbeck TR.

JAMA. 2010 Sep 1;304(9):967-75. doi: 10.1001/jama.2010.1237.

17.

Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers.

Grann VR, Patel PR, Jacobson JS, Warner E, Heitjan DF, Ashby-Thompson M, Hershman DL, Neugut AI.

Breast Cancer Res Treat. 2011 Feb;125(3):837-47. doi: 10.1007/s10549-010-1043-4. Epub 2010 Jul 20.

18.

Single-nucleotide polymorphisms in the p53 signaling pathway.

Grochola LF, Zeron-Medina J, Mériaux S, Bond GL.

Cold Spring Harb Perspect Biol. 2010 May;2(5):a001032. doi: 10.1101/cshperspect.a001032. Epub 2009 Dec 9. Review.

19.

Are estrogen receptor-positive breast cancers in BRCA1 mutation carriers sporadic?

Lakhani SR, Khanna KK, Chenevix-Trench G.

Breast Cancer Res. 2010;12(2):104. doi: 10.1186/bcr2483. Epub 2010 Mar 19.

20.

The prevention of hereditary breast and ovarian cancer: a personal view.

Narod S.

Hered Cancer Clin Pract. 2004 Feb 15;2(1):5-10. doi: 10.1186/1897-4287-2-1-5.

Items per page

Supplemental Content

Write to the Help Desk